These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37457283)

  • 1. Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy.
    Godinez H; Xu Q; McMann TJ; Li J; Mackey TK
    Front Public Health; 2023; 11():1073813. PubMed ID: 37457283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C
    AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsupervised Machine Learning to Detect and Characterize Barriers to Pre-exposure Prophylaxis Therapy: Multiplatform Social Media Study.
    Xu Q; Nali MC; McMann T; Godinez H; Li J; He Y; Cai M; Lee C; Merenda C; Araojo R; Mackey TK
    JMIR Infodemiology; 2022; 2(1):e35446. PubMed ID: 37113799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
    Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
    J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men.
    Fisher CB; Fried AL; Ibrahim Puri L; Macapagal K; Mustanski B
    PLoS One; 2018; 13(7):e0200560. PubMed ID: 30044845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
    McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
    JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reddit on PrEP: Posts About Pre-exposure Prophylaxis for HIV from Reddit Users, 2014-2019.
    Loosier PS; Renfro K; Carry M; Williams SP; Hogben M; Aral S
    AIDS Behav; 2022 Apr; 26(4):1084-1094. PubMed ID: 34536176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.
    Fields SD; Tung E
    Infect Dis Ther; 2021 Mar; 10(1):165-186. PubMed ID: 33569743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.
    Grov C; Westmoreland DA; D'Angelo AB; Johnson J; Nash D; Daskalakis DC;
    AIDS Behav; 2021 May; 25(5):1396-1404. PubMed ID: 32729019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
    Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M
    BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-exposure Prophylaxis (PrEP) Information on Instagram: Content Analysis.
    Walsh-Buhi E; Houghton RF; Lange C; Hockensmith R; Ferrand J; Martinez L
    JMIR Public Health Surveill; 2021 Jul; 7(7):e23876. PubMed ID: 34061759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study.
    Shan D; Xue H; Yu F; Zan X; Liu H; Liu J; Han M; Zhang D
    J Med Internet Res; 2023 May; 25():e42729. PubMed ID: 37204828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
    Mimiaga MJ; Closson EF; Battle S; Herbst JH; Denson D; Pitts N; Holman J; Landers S; Mansergh G
    AIDS Patient Care STDS; 2016 Oct; 30(10):484-489. PubMed ID: 27749110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.